Blueprint Medicines (NASDAQ: BPMC) Corporation, a commercial-stage biotechnology company with a market capitalization of $8.27 billion, has been making significant strides in the pharmaceutical ...

In conclusion, Blueprint Medicines stands at a pivotal juncture with its recent acquisition by Sanofi and the continued success of Ayvakit. The stock has demonstrated strong momentum, with a 37.31% ...

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 potential. Click for more on SNY and BPMC.

Sanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases. The purchase includes a 27% premium per share and could total nearly $9.5 ...

Sanofi agreed to acquire Blueprint Medicines, a Cambridge, Mass.-based biotech focused on rare immunology diseases, for $9.1 billion in cash and up to $400 million in earnouts. Why it matters ...

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research ...

CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts ...